[ Alzheimer’s Drug Discovery Foundation – Drug Development Program| Research Funding ]
Event details
| Date | 10.07.2020 |
| Category | Call for proposal |
Aim: The goal of this request for proposals (RFP) is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years.
Specifically, the Drug Development RFP supports:
The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Both novel programs and repurposing/repositioning of approved or clinically safe therapies from other disease indications are appropriate for this RFP.
Current target areas of interest include:
Funding: max. $600,000
Duration: 1 year
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Deadlines for proposal submissions occur quarterly. Applications are reviewed in a two-step process: Letters of Intent (LOI) are the first step. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Summer Deadlines: 10-July-20 (letter of intent)
07-Aug-20 (full proposal, by invitation)
Autumn Deadlines: 09-Oct-20 (letter of intent)
06-Nov-20 (full proposal, by invitation)
Further information
Specifically, the Drug Development RFP supports:
- Preclinical pharmacokinetics, pharmacodynamics, target engagement, and preliminary rodent tolerability
- In vivo efficacy or proof-of-concept studies
The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Both novel programs and repurposing/repositioning of approved or clinically safe therapies from other disease indications are appropriate for this RFP.
Current target areas of interest include:
- Epigenetics
- Inflammation
- Mitochondria & metabolic function
- Neuroprotection
- Proteostasis
- Synaptic activity and neurotransmitters
- Vascular function
- Other aging target (e.g. senescent cells)
- Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process
Funding: max. $600,000
Duration: 1 year
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Deadlines for proposal submissions occur quarterly. Applications are reviewed in a two-step process: Letters of Intent (LOI) are the first step. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Summer Deadlines: 10-July-20 (letter of intent)
07-Aug-20 (full proposal, by invitation)
Autumn Deadlines: 09-Oct-20 (letter of intent)
06-Nov-20 (full proposal, by invitation)
Further information
- More information about the program is available here
- Detailed application instructions are here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free